|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-12-17
|
|
pubmed:abstractText |
Milataxel is a novel taxane analog, with evidence of enhanced preclinical activity compared to paclitaxel and docetaxel, especially in cell lines that over express P-glycoprotein. Based on preclinical data that milataxel may be active in colorectal cancer (CRC), a phase II study was performed in patients with advanced previously treated CRC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
pubmed-author:BergDanielD,
pubmed-author:BernardStephenS,
pubmed-author:BresciaFrankF,
pubmed-author:CohnAllenA,
pubmed-author:FrenetteGaryG,
pubmed-author:HochsterHowardH,
pubmed-author:LockhartA CraigAC,
pubmed-author:MacdonaldJohnJ,
pubmed-author:MelinSusanS,
pubmed-author:PicusJoelJ,
pubmed-author:RaftopoulosHaralambosH,
pubmed-author:RamanathanRamesh KRK
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
453-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17516069-Adult,
pubmed-meshheading:17516069-Aged,
pubmed-meshheading:17516069-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17516069-Area Under Curve,
pubmed-meshheading:17516069-Blood Cell Count,
pubmed-meshheading:17516069-Colorectal Neoplasms,
pubmed-meshheading:17516069-Dose-Response Relationship, Drug,
pubmed-meshheading:17516069-Female,
pubmed-meshheading:17516069-Half-Life,
pubmed-meshheading:17516069-Humans,
pubmed-meshheading:17516069-Male,
pubmed-meshheading:17516069-Middle Aged,
pubmed-meshheading:17516069-Paclitaxel,
pubmed-meshheading:17516069-Treatment Failure
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.
|
|
pubmed:affiliation |
Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. ramanathanrk@upmc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
